ArticleAmerican journal of translational research2024

Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients.

Shuhong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.